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The dynamic movement of radiation beam in real-time tumor tracking may cause 
overdosing to critical organs surrounding the target. The primary objective of 
this study was to verify the accuracy of the 4D planning module incorporated in 
CyberKnife treatment planning system. The secondary objective was to evaluate 
the error that may occur in the case of a systematic change of motion pattern. Mea-
surements were made using a rigid thorax phantom. Target motion was simulated 
with two waveforms (sin and cos4) of different amplitude and frequency. Inversely 
optimized dose distributions were calculated in the CyberKnife treatment planning 
system using the 4D Monte Carlo dose calculation algorithm. Each plan was de-
livered to the phantom assuming (1) reproducible target motion,and (2) systematic 
change of target motion pattern. The accuracy of 4D dose calculation algorithm 
was assessed using GAFCHROMIC  EBT2 films based on 5%/3 mm γ criteria. 
Treatment plans were considered acceptable if the percentage of pixels passing the 
5%/3 mm γ criteria was greater than 90%. The mean percentages of pixels passing 
were 95% for the target and 91% for the static off-target structure, respectively, 
with reproducible target motion. When systematic changes of the motion pattern 
were introduced during treatment delivery, the mean percentages of pixels passing 
decreased significantly in the off-target films (48%; p  < 0.05), but did not change 
significantly in the target films (92%; p = 0.324) compared to results of reproduc-
ible target motion. These results suggest that the accuracy of 4D dose calculation, 
particularly in off-target stationary structure, is strongly tied to the reproducibility 
of target motion and that the solutions of 4D planning do not reflect the clinical 
nature of nonreproducible target motion generally.   
PACS numbers: 87.53.Ly, 87.55.km
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I. InTRoducTIon
Real-time tumor tracking (RTRT) has been increasingly employed in stereotactic body radio-
therapy (SBRT).(1,2) Through continuous adaptation of radiation beam to the moving target, 
RTRT can effectively eliminate the systematic and random errors due to target motion and 
thus allow great potential of dose escalation by significant margin reduction.(3) CyberKnife  is 
one of the few RTRT systems that are presently applied to clinical SBRT treatments. Tumor 
tracking by CyberKnife is implemented under two subsystems of the target localization system 
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(TLS) called Synchrony Respiratory Tracking System (RTS) and the XSight Lung Tracking 
System. Both tracking systems involve a correspondence model that combines continuously 
acquired respiratory signal and continually updated kV stereoscopic image pairs of internal 
fiducial markers (i.e., Synchrony RTS) or soft tumor tissue (i.e., XSight Lung Tracing System). 
During treatment, these tracking systems measure the external breathing signal to predict the 
tumor position based on the correspondence model and drive the robotic arm to track the rigid 
target movement accordingly. 
One major concern of these beam tracking treatments is that standard treatment plans are 
created on static anatomy and are subsequently delivered to dynamically changing anatomy. 
That is, treatment plans of 3D nature are delivered in 4D manner. Because internal organ motion 
is nonrigid, the positions of the target and hence the radiation beam relative to other critical 
organs, such as esophagus and spinal cord, can change during respiration. A few studies have 
demonstrated that failure to account for the organ deformation and the dynamic tracking beam 
movement in the treatment planning process may cause unexpected loss of target dose coverage 
and increase of critical organ doses.(4,5) To resolve this problem, a 4D dose optimization and cal-
culation algorithm has been added to the CyberKnife treatment planning system (TPS). Similar 
to other 4D dose calculation methods,(6,7) this algorithm takes 4D CT as input to provide the 
breathing geometry and determine the target trajectory, and uses deformation image registration 
(DIR) as a tool to deform the dose distribution of one breathing geometry to the others. Theoreti-
cally, 4D dose calculation should have the potential to minimize the errors between delivered 
and planned dose distributions.(8) However, several studies have shown that interpolation errors 
of the DIR and dose calculation may produce inaccurate dose distributions.(9,10) Furthermore, 
4D dose calculation shares the same assumption with conventional 3D dose calculations that the 
breathing motion during imaging and treatment is reproducible. Unfortunately, this assumption 
does not hold in most clinical situations. Different studies have previously demonstrated that 
tumors may change in their motion trajectory, amplitude, frequency, or baselines on different 
time scale, causing intrafractional and interfractional variations of the patient model.(1,11) 4D 
treatment planning based on a single patient breathing model can introduce systematic error 
that cannot be simply averaged out by multiple treatment deliveries, as has been discussed by 
Evans et al.(12) This work aimed to use a commercial dynamic thorax phantom to investigate the 
accuracy of 4D CyberKnife treatment plans and also to evaluate the validity of 4D calculation 
in the presence of a systematic change in motion pattern. 
 
II. MATERIALS And METHodS
Figure 1 shows the dynamic thorax phantom (Model 18043, CIRS Inc., Norfolk, VA used in this 
study. The thorax body houses two cylinder rods made of lung- and trabecular bone-equivalent 
materials, respectively. The lung-equivalent rod has a target film cube with a 25 mm (diameter) 
simulated tissue tumor sphere that accommodates two orthogonal radiochromic films. The 
bone-equivalent rod also contains a cylindrical critical structure that accommodates film in the 
coronal plane. The dynamic phantom has a motion controller connected to a motion actuator 
to produce three-dimensional translation and rotation motion of the lung-equivalent rod. To 
facilitate phantom setup, there are four metal fiducials embedded in the phantom, two affixed to 
the target and the other affixed to the cord cylinder. In addition, the phantom has an independent 
motion platform providing the external breathing signal needed to build the correspondence 
model of Synchrony RTSTM (CyberKnife; Accuray Inc., Sunnyvale, CA). 
The simulated target was programmed to move in seven different patterns (Table 1). Both 
simple one-dimensional (1D) and 3D motions were included. The choice of motion period T 
and amplitude A were based on the analysis of patients treated at our institute, who showed an 
averaged 3D motion of 8.6 mm and period of four seconds. A large 30 mm superior–inferior 
(SI) motion was also included as an extreme scenario. The influence of asymmetric motion 
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was investigated using a sin waveform and a cos4 waveform. The cos4 function has been dem-
onstrated to provide the best fit to the population data.(13) 
A 4D CT study was available for each motion pattern. The phantom in motion was 4D CT 
scanned in cine mode on a GE LightSpeed 64-slice CT (General Electric Medical Systems, 
Waukesha, WI) with 1.5 mm slice thickness. High resolution breathing signal acquired with 
the real-time position management system (RMP, Varian Medical Systems, Palo Alto, CA) was 
used to retrospectively sort the 4D CT dataset into ten 3D CT series that were equally spaced 
in time. 
Once the ten 3D CT series were reconstructed, they were input to the MultiPlan TPS v.4.0.x 
(Accuray Inc., Sunnyvale, CA). The 4D dose calculation algorithm implemented in the  MultiPlan 
Fig. 1. Components of the dynamic thorax phantom.  
Table 1. Summary of the programmed target motion. 
 Motion Parameters 
 Motion Superior–Inferior Anterior–Posterior Left–Right Period
 Pattern (mm) (mm)  (mm) (s) Waveform
 M_1 10 5 2 4 cos4
 M_2 20 5 2 3.5 cos4
 M_3 20 5 2 4 cos4
 M_4 20 5 2 5 cos4
 M_5 30 0 0 4 sin
 M_6 10 0 0 4 sin
 M_7 10 0 0 3 sin
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TPS was described in details by West et al.(14) In brief, it begins with nonrigid  image registra-
tions, or deformable image registrations (DIR), between individual 3D CT images in the 4D 
CT study using a hybrid point-intensity–based approach. The 4D planning system  allowed 
virtual control points to be placed in regions with low contrast for improving the DIR results. 
For each 4D CT study, we added a total of ten control points on and near the off-target mea-
surement films to improve the DIR. The DIR takes as input an anatomical voxel location in the 
reference 3D CT image and returns as output the deformed position of this anatomical voxel 
in the other 3D CT images. The resulting deformation vector fields (DVF) are represented by 
a combination of third-order B splines. In Fig. 2, the left and right columns show the result-
ing deformed geometry at the end-inhale and midventilation phases, respectively. Due to the 
motion-related artifacts associated with the 4D CT images, the deformation yielded apparent 
distortion of the spherical target (Figs. 2(a) and 2(b), as well as the neighboring cylindrical 
cord structure (Figs. 2(c) and 2(d).  
To incorporate the dynamic beam motion and organ deformation, the beam arrangement 
was shifted according to the positions of the fidudical markers in the 4D CT study, and a stan-
dard dose calculation on each of the individual 3D CT images followed. The dose matrix of 
the reference phase was then deformed to other phase, and doses at each deformed position in 
these static dose matrices were interpolated back to the reference dose grid of the deformed 
dose voxel. Finally, the deformed doses were summed and weighted by the relative width of 
the time bin for each 3D CT frame to compose the 4D dose in the reference CT space image 
on which structure contours were delineated (Fig. 3) and dose distribution was evaluated. In 
this study, the target and critical organs, beam geometry, and dose grid were all defined on the 
reference CT dataset at the end of exhale (EOE) phase. 
Based on the 4D dose calculation framework described above, 4D optimization was carried 
out for each of the motion patterns. The optimization process was similar to standard 3D planning 
in the way the optimization objectives were specified; the optimization process simply involved 
Fig. 2. Results of the deformable image registrations (DIR). The deformation yielded apparent distortion of the spherical 
target ((a) and (b)) and the cord structure ((c) and (d)) in the split view. 
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substituting the 4D dose matrices for the 3D dose matrices. Optimization objectives were to 
achieve 99% target coverage, target dose heterogeneity < 30%, and minimal monitor units. It 
should be noted that the target for optimization was 9 mm less in diameter than the actual phan-
tom target in order to fit the target dose distributions to the active film measurement area. The 
4D dose distributions were produced with the ray-tracing algorithm with equivalent path length 
(EPL) heterogeneity correction(15) and 4.2 Gy × three fractions was prescribed to the planning 
target’s surface. The fraction dose was scaled to 4.2 Gy in order to accommodate the dose range 
applicable to the EBT2 film dosimetry (up to 10 Gy for red channel  measurement). 
Because of sharp dose falloff, off-target dose to the cord structure was so low that dose 
measurements were difficult. Therefore, other sets of 3D optimized plans were created with 
intention to introduce large dose spillage to the measurement film plane of the cord structure. 
Subsequently, the optimized 3D beam set was applied to 4D dose calculation. Final 4D dose 
distributions were calculated for the target and cord plans with the fast Monte Carlo (MC) 
algorithm at 1% relative uncertainty.(15) Resulting dose distributions were Gaussian smoothed 
(σ = 0.6%) to reduce statistical noise. The MC dose calculation voxel was approximately 
1.05 × 1.05 × 1.5 mm3. It is important to note that the electron transport algorithm calculated 
absorbed dose to variable density water, which is not strictly identical to absorbed dose to 
medium. However, the difference between these quantities is negligible for most of the bio-
logical tissues (including lung and bone), but may be greater in nonbiological materials such 
as metallic implants.(16) 
Treatment plans were delivered in two ways. First, the rigid phantom was irradiated according 
to the treatment plans assuming reproducible target motion during imaging and beam delivery. 
Second, we evaluated the errors of 4D dose calculation arising from possible systematic vari-
ability of target motion by delivering each plan to the phantom moving a motion pattern that 
is systematically different from the one used in treatment planning. The reason we carried out 
this evaluation is that, unlike the error of random target motion that has been shown to average 
out when multiple fractions are delivered, error introduced by systematic change of the target 
motion pattern in treatment planning and in actual treatments is likely to cause considerable 
discrepancy between the planned and actual dose distributions.(12) A 3D plan created with MC 
dose calculation on static 3D images at EOE was also delivered to the phantom in the absence 
of motion for benchmarking. Table 2 summarizes the dose measurements for different treat-
ment delivery methods.      
GAFCHROMIC EBT2 films (International Specialty Products, Wayne, NJ) were used for 
dose measurements because of its high spatial resolution, minimal angular and energy response 
compared to other common dosimetry tools such as ionization chamber and thermoluminescence 
Fig. 3. Example of the plan dose distribution showing the geometric relation between the moving target and the static 
cord structure.
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dosimeters.(17,18) Dose measurements were performed separately for the coronal and transverse 
films in the target, so for each motion pattern the same plan was delivered six times. Off-target 
dose measurements of the cord structure were made only for linear motions (M_5 to M_7). The 
exposed films were scanned within 24 hours postirradiation on an Epson Expression 1000XL 
flatbed scanner (Epson America, Long Beach, CA) to produce a 48 bit color (RGB) images of 
150 dots per inch resolution. Each exposed film was scanned three times and averaged to reduce 
the scanner electronic noise. No marker-dye correction for the nonuniformity of EBT2 film was 
made for the calibration films and measurement films because of the limited dose sensitivity of 
blue channel images above 4 Gy.(19) At lower dose range, Richley et al.(20) have demonstrated 
that intra- and intersheet inhomogeneity of film thickness contributed to 2.4% dose uncertainty 
at 200 cGy. Absolute EBT2 film dosimetry without applying blue channel corrections have 
been reported to show good results in quality assurance of intensity-modulated radiotherapy.
(18) The red channel images were registered to the dose plane exported from the TPS at the 
EOE phase with the FilmQA software (3cognition LLC. Wayne, NJ) and were analyzed based 
on the γ metric. The films were compared to the calculated dose based on the γ metric, which 
aims to quantitatively compare the measured and calculated dose distributions by dose differ-
ences and distance to agreement (DTA). In principle, the γ criteria should be set in accordance 
to desired dosimetric accuracy of the treatments. Considering the dose uncertainty of EBT2 
film dosimetry and the increased sensitivity of measurement errors to the large dose gradient 
of SBRT, the passing criteria were set at 5% of the absolute dose difference and 3 mm DTA 
(5%/3 mm) assuming 1 mm error in residual tracking accuracy and 2 mm error associated with 
the deformable image registration and film alignment during measurement and analysis. The 
5%/3 mm criteria was less stringent than the 3%/3 mm criteria recommended in the AAPM 
Report 135 for quality assurance of robotic radiosurgery,(21) but it was deemed acceptable for 
heterogeneous phantom by the Radiological Physics Center (RPC) for National Cancer Insti-
tute clinical trials. We further considered the acceptance level of percentage of pixels passing 
the 5%/3 mm to be ≥ 90%. We compared the percentages of pixels passing among the various 
motion patterns (sin vs. cos4), and with and without systematic change of motion patterns (e.g., 
reproducible motion vs. increased and decreased amplitude), using Mann-Whitney U tests. All 
tests were considered significant at p < 0.05.
 
Table 2. Summary of the treatment delivery and the types of motion variability tested.  
 Delivered Plan Actual Motion Motion Variability Tested
 M_1 / M_ 3 M_1 / M_3 Baseline
 M_1 M_3  Increasing amp. (3D motion)
 M_3 M_1 Decreasing amp. (3D motion)
 M_2 / M_4 M_2 / M_4 Baseline
 M_4 M_2 Increasing freq. (3D motion)
 M_2 M_4 Decreasing freq. (3D motion)
 M_6 / M_7 M_6 / M_7 Baseline
 M_6 M_7 Increasing freq. (1D motion)a
 M_7 M_6 Decreasing freq. (1D motion)a
 M_5 / M_7 M_5 / M_7 Baseline
 M_5 M_7 Decreasing amp.+ increasing freq. (1D motion)a
 M_7 M_5 Increasing amp.+ decreasing freq. (1D motion)a
 M1 / M_6 M 6 / M_1 Baseline
 M_1 M_6 Decreasing amp. (3D vs. 1D motion) + waveform (cos4 vs. sin)
 M_6 M_1 Increasing amp. (1D vs. 3D motion) + waveform (sin vs. cos4)
 M_5 / M_6 M_5 / M_6 Baseline
 M_5 M_6 Decreasing amp. (1D motion)a,b
 M_6 M_5 Increasing amp. (1D motion)a,b
aTested for off-target films; bnot tested for target films.
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III. RESuLTS 
Table 3 shows the mean percentages of pixels passing the 5%/3 mm γ criteria with the film 
measurements for benchmark static plan and reproducible motion plans. For the benchmark 
3D MC plan, all pixels evaluated passed at the tighter 3%/3 mm γ criteria as a consequence of 
excellent agreement between the measured and calculated dose distributions (Fig. 4). Overall, 
the percentages passing for the 4D MC plans were 95% ± 7% (mean ± one standard devia-
tion (SD)). Out of 42 films, the percentage of pixels passing was smaller than 90% in eight 
films. In the failing films, the average percentages of pixels passing were 85% for six coronal 
films, and 77% for two transverse films, respectively. No significant difference was observed 
between 1D sin and 3D cos4 waveforms (p = 0.27). Figure 5 shows the overlaid measured and 
calculated relative isodose lines in the transverse and coronal planes for a 3D cos4 motion 
(M_3). Although these film planes satisfied the acceptance criteria, the overlaid isodose lines 
exhibited some regions of disagreement, particularly in the coronal plane where misalignment 
of the isodose lines deteriorated from inferior to superior direction (i.e., from exhalation to 
inhalation) (Figs. 5(a) and 5(b)). Fig.5(c) and 5(d) clearly indicated that the 4D plan reproduced 
the dose profile fairly well in the anterior–posterior motion axis, but failed to model the dose 
profile in the principal motion axis. It stretched the dose profile to superior (end-exhale) and 
compressed the dose profile to inferior (end-inhale). This trend was observed mainly in 4D 
plans of cos4 motion. 
Table 3. Percentage of pixels passing the 5%/3 mm criteria in the moving target and cord cylinder for various motion 
patterns and dose calculation methods. 
   Percentages of Pixels 
 Motion Pattern Film Orientation Passing 5%/3 mm
 Target  
 M_1 Coronal 94±8
  Transverse 89±12
  Mean ± SD 92±5
 M_2 Coronal 91±8
  Transverse 92±10
  Mean ± SD 91±4
 M_3 Coronal 95±7
  Transverse 100±0
  Mean ± SD 98±4
 M_4 Coronal 94±7
  Transverse 99±1
  Mean ± SD 96±3
 M_5 Coronal 99±1
  Transverse 100±0
  Mean ± SD 99±0
 M_6 Coronal 96±6
  Transverse 100±0
  Mean ± SD 97±3
 M_7 Coronal 86±6
  Transverse 97±5
  Mean ± SD 91±1
 Overall Mean ± SD 95±7
  
 Off-target OAR 
 M_5 Coronal 99±2
 M_6 Coronal 88±8
 M_7 Coronal 85±15
 Overall Mean ± SD 91±10
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For off-target structure, three films were failed and the mean percentage of pixels passing was 
91% ± 11%. Separate evaluations of the dose difference maps and the distance-to-agreement 
maps demonstrated that failing regions were mainly attributed to dose difference. Figure 6 
shows the measured dose distributions of the same treatment plan. Taking out the uncertainty 
of experiment setup, the slight difference between these dose distributions was presumably a 
result of the random relationship between breathing phase and beam-on time. 
The measurement results for irreproducible target motion were summarized in Table 4. The 
results in the target and the off-target cord were different. For the target, the average passing 
rates were 92% ± 6%. Out of 60 films, the percentages of pixels passing were smaller than 
90% in ten coronal films (82% ± 7%) and seven axial films (77% ± 9%). The γ passing rate was 
not significantly different between reproducible and irreproducible target motions (p = 0.324). 
Also, the γ passing rate did not show any significant change for each type of motion variation 
compared to the results obtained with the corresponding plan that was delivered to reproduc-
ible motion. As a comparison to the dose distributions of reproducible motion shown in Fig. 5, 
Fig. 4. Gamma (3%/3 mm) distributions (top row), overlaid measured (thin solid line), calculated (thick solid line) and 
isodose lines (bottom row) in the transverse and coronal films of the benchmark static Monte Carlo dose plan. 
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Fig. 5. Overlaid measured (thin solid line) and calculated (thick solid line) dose distributions in the transverse film 
(a) and coronal film (b) are showed for the same 4D plan in Fig. 2. Calculated and measured dose profiles corresponding 
to the solid lines in (a) and (b) are plotted in (c) and (d). The dashed lines represent the target region.  
Measured dose = thin solid lines; calculated dose = thick solid lines.
Fig. 6. Dose distributions measured when the same treatment plan for motion pattern M_7 was delivered three times. 
Random relationship between respiratory phase and beam-on time resulted in slightly different dose distributions.
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Fig. 7 shows the overlaid calculated and measured dose distribution for treatment plan that was 
created with the same motion pattern as in Fig. 5 (M_3) and was intentionally delivered to the 
phantom moving in a different motion pattern (M_1) of reduced motion range. Similarly, the 
calculated dose distribution and profile demonstrated greater discrepancies with the measured 
dose distribution inside and outside the target area in the coronal film than in the axial film. The 
effect of reduced motion range was that the delivered dose was concentrated to a smaller region 
of higher dose inside the target (Fig. 7(b) and 7(d)). On the other hand, the systematic change of 
motion pattern strongly affected the doses to the off-target structures, as all measurements had 
percentages of pixels passing well below 90% with a mean of 48% ±14%. The γ passing rate 
was significantly lower in irreproducible motions than in reproducible motions (p < 0.05). As 
illustrated in Fig. 8, the effect of increased and decreased motion amplitude was mirrored. The 
increased motion amplitude spread out the off-target dose distribution, decreasing the region of 
Table 4. Percentages of pixels passing 5%/3 mm gamma criteria with introduction of various systematic changes of 
motion pattern. 
    Percentages of Pixels  Percentages of Pixel
 Delivered Actual  Passing 5%/3 mm in Passing 5%/3 mm in
 Plan Motion Motion Variability Coronal Films Axial Films
 Target    
 M_1 M_3 Amp.  97±3 99±2
   (3D motion) 
 M_3 M_1 Amp.  94±6 99±2
   (3D motion) 
 M_2 M_4 Freq.  92±9 84±7
   (3D motion) 
 M_4 M_2 Freq.  98±2 74±16
   (3D motion) 
 M_6 M_7 Freq.  92±6 99±1
   (1D motion) 
 M_7 M_6 Freq.  91±9 100±0
   (1D motion) 
 M_5 M_7 Amp. + Freq. 96±5 96±6
   (1D motion) 
 M_7 M_5 Amp. + Freq. 81±14 92±10
   (1D motion) 
 M_1 M_6 Amp. + Waveform 90±8 100±0
   (3D cos4 vs.1D sin) 
 M_6 M_1 Amp. + Waveform 84±9 97±3
   (3D cos4 vs.1D sin) 
 Off-target Cord    
 M_5 M_6 Amp.  59±2
   (1D motion)  
 M_6 M_5 Amp.  46±15
   (1D motion)  
 M_6 M_7 Freq.  35±4
   (1D motion)  
 M_7 M_6 Freq.  48±7
   (1D motion)  
 M_7 M_5 Amp. + Freq. 34±15
   (1D motion)   
 M_5 M_7 Amp. + Freq. 62±10
   (1D motion)
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Fig. 7. Overlaid calculated (thick solid line) and measured (thin solid line) dose distributions in the axial (left column) and 
coronal (right column) target films are shown for treatment plan that was created based on motion pattern M_3 and was 
intentionally delivered to the phantom moving in motion pattern M_1. Calculated and measured dose profiles corresponding 
to the solid lines in (a) and (b) are plotted in (c) and (d). The dashed lines represent the target region.  
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high dose and increasing the region of low dose (Fig. 8(a)). The decreased motion amplitude 
squeezed the isodose lines, increasing the high-dose region while decreasing the low-dose 
region (Fig. 8(b)). In this case, the 50% and 30% isodose lines were shifted by a maximum 
distance of 6.5 mm and 8.7 mm, respectively. Of more importance is that the maximum dose 
was increased by more than 10% compared to the plan estimate.  
 
IV. dIScuSSIon
4D dose calculation has been used to explicitly account for the dose blurring effect of intrafrac-
tional target motion. Previous studies have evaluated and compared 3D and 4D dose calculations 
with measured target doses using rigid and deformable lung phantoms in conventional radio-
therapy.(6,22) This work aimed to evaluate the accuracy of a commercial 4D dose calculation 
algorithm for CyberKnife.        
For the moving target, the mean percentages of pixels passing were 95% when the target 
motion was consistent between treatment planning and delivery. Introduction of systematic 
increasing and/or decreasing amplitude and frequency during actual treatments did not lead to 
significant differences in the passing rates (p > 0.05). These results were not surprising. Previ-
ously, Niousitkou et al.(23) showed 97% pixels passing at 3%/3 mm γ criteria, even if treatment 
plans were created for deformable lung phantom using 3D dose calculation and simple equiva-
lent path length correction for heterogeneity. With real-time tumor tracking of target, the dose 
blurring due to respiratory motion is minimized because the target itself did not appear to be 
moving while it was being tracked by the treatment beams. Conversely, off-target structures, 
such as spinal cord that did not move in the same way with the tracking beams, appeared to be 
moving and dose blurring was primarily manifested on these structures. As shown in Fig. 6, 
4D dose calculation algorithm adequately predicted the dose distributions in the off-target cord 
structure in reproducible motions, and six of the nine measured off-target films satisfied 90% 
Fig. 8. Measured dose distributions (thin solid line) with 4D plans (thick solid line) delivered in the presence of systematic 
increase of motion amplitude (a) and systematic decrease of motion amplitude (b) during treatment deliveries.  
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pixels passing at 5%/3 mm with a mean passing rate of 91%. Nonetheless, 4D dose calculation 
algorithm apparently failed to predict the dose distribution when the target motion was not the 
same as captured in the 4D CT dataset. In such cases, all off-target measured films failed, and 
the mean percentage of pixels passing reduced significantly to 48%. In order to make 85%–90% 
of pixels passing the evaluations, the γ criteria had to be relaxed to 10%/5 mm and even 15%/7 
mm. It clearly suggested that the sensitivity of 4D dose calculations to variation of target mo-
tion differs by structures of interest. It should be noted that our results were based on rigid 
geometry and rigid target motion. However, errors due to differential target motion and varying 
lung density should be negligible if adequate safety margin is used.(5,24) Errors due to variation 
of beam paths as treatment beams traversing through different materials were also expected to 
averaged out for a large number of beams (> 100 beams) used in Synchrony treatment. 
One of the difficulties to verify 4D dose distributions was the selection of the calculated 
dose plane for comparisons with measured films. From Fig. 5, dose plane exported using the 
centroid position of the target at the end-exhale led to a systematic shift from the measured dose 
distributions because the end-exhale phase did not correspond to the time-weighted average 
target position. Furthermore, the time-weighted average position, as portrayed on the 4D CT 
data, may not necessarily correspond to the same geometrical point if the motion pattern has 
changed in the actual treatment. Such discrepancy between the exported dose plane and the 
measured film plan added to the uncertainty of the evaluated accuracy of the 4D dose calcula-
tions. Indeed, it would not be possible to outline the target and to define the dose plane at the 
time-weighted average position or midventilation phase because of significant motion artifacts 
associated with these reconstructed 4D CT images. For the same reason, we avoided using the 
time-weighted average images as the reference frame to register with other CT frames because 
it would affect all the calculated DVFs. Similarly, the distorted medium density maps, when 
applied to determine the energy lost, step length, and step direction in the particle transport 
processes, were expected to contribute to significant error of the resulting dose distributions. For 
instance, the increased CT number caused by the distortion of metal markers (Fig. 2(b)) may 
cause the electrons to terminate their tracks and deposit their energies that would be otherwise 
carried away from the spot. On the other hand, the approximate efficiency improvement tech-
niques implemented in the high-energy inelastic interaction calculation for electron transport, 
which may cause substantial difference between absorbed dose to variable density water in the 
MultiPlan Monte Carlo algorithm and absorbed dose to medium,(25)  were expected to exaggerate 
errors of the dose calculation results given the significant distortion of the high-density metal 
markers in the CT images. The errors of DIRs and dose calculations due to image artifacts can 
be clearly visualized by comparing the dose distribution calculated on static geometry (Fig. 4) 
and on temporally changing geometry (Fig. 5). As noted in Fig. 5, the artifacts were primarily 
manifested in the flexuous isodose lines in the coronal plane which gradually became smooth 
to the inferior of the dose distribution (i.e., in the exhalation direction). The better agreement 
between the calculated and measured dose distributions to inferior can be explained by the 
improved accuracy of the DIRs and dose calculations.    
According to West et al.,(14) the 4D dose calculation algorithm distributed the dose or MU 
of each beam to all breathing phases according to their relative weights. That is, the dose 
(MU) of each beam was phase-locked. But when the beam was started at any random breath-
ing phase, the dose and MU was redistributed randomly. In the worst scenario, some phases 
that would have received some doses would end up receiving no doses before the beam had 
delivered all MUs. However, this situation is unlikely because SBRT usually delivers up to 
20 Gy per fraction and the duration of each beam shall be comparable to breathing cycle. Even 
if the fractional dose of this study was scaled down by a factor of 4.5 as compared to the actual 
treatment dose, the effect of random relationship between the breathing phase and the beam-on 
time was negligible. It led to slight isodose misalignments between measurements, as shown 
in the off-target films (Fig. 6). 
316    Chan et al.: Verification of four-dimensional dose calculation for CyberKnife  316
Journal of Applied clinical Medical Physics, Vol. 13, no. 6, 2012
This work focused on evaluating the 4D dose calculation algorithm of the CyberKnife TPS. 
We did not compare the accuracy of 3D and 4D dose calculations. In theory, 4D dose optimiza-
tion and calculation should provide better target dose coverage by taking explicit account of 
the organ deformation and motion. The inclusion of beam movements in the calculation should 
also improve the estimated doses to off-target critical structures. 4D dose calculation requires 
interpolations of dose matrices between multiple geometries. Few studies have suggested that 
the interpolation error is more pronounced in high-dose gradients.(9,26) This may have some 
implication in SBRT treatment because treatment dose is often prescribed to lower isodose line 
producing highly heterogeneous dose distributions. The disagreement between the calculated 
and measured dose profile observed in this study may also be a consequence of interpolation 
errors (Fig. 5). It is possible to reduce the interpolation error by using smaller dose calculation 
grid at the expense of increased calculation time, which is already ten times more than standard 
3D dose calculation.(27) Nevertheless, there are still inherent interpolation errors that cannot be 
reduced by using smaller dose grid without considering the conservation of mass and energy 
in the dose mapping process.(10) On the other hand, actual organ motion and deformation is 
generally not known a priori, and the planning 4D CT contains motion information at a spe-
cific time point. Interfractional and intrafractional variations of target motion range, period, 
and volume are frequently noted in lung radiotherapy.(1,28) Systematic and random variation 
of target motion results in shifting and blurring off-target dose distributions and thus narrow-
ing the advantages of 4D dose calculation to better predict the off-target doses. That 4D dose 
optimization and calculation can facilitate further margin reduction is therefore questionable. 
On the other hand, the planning risk volume (PRV) has been recommended by ICRU Report 83 
for protection of organs-at-risk from overdosed.(29) Although studied data of positional varia-
tions of these organs can serve as the baseline for setting up the PRVs, Stroom and Heijmen(30) 
have demonstrated the limitation of PRV with organs that are organized in serial function units 
because of the nonlinear behavior of these organs with dose gradient. As indicated in Fig. 8(b), 
a systematic decrease of target motion concentrated the delivered dose to a smaller zone of 
the cord structure and increased the maximum dose by > 10%, compared to the plan estimate. 
This may have great impacts on the simulated cord structure that is organized in serial func-
tion units, particularly when the original planned maximum dose has already been touching 
the organ tolerance dose. This problem cannot be simply resolved by adding a PRV to the cord 
structure. To make 4D planning of real-time tumor tracking robust against uncertainty of the 
virtual patient model, robust optimization proposed by Heath et al.(31) should be incorporated 
in the current 4D treatment planning module in the CyberKnife TPS.   
 
V. concLuSIonS
This work demonstrated that the commercial 4D dose calculation algorithm for real-time tumor 
tracking SBRT was able to account for the dynamic beam movement and provided adequate 
predictions of the doses to moving target, as well as static off-target structure with reproduc-
ible target motion. However, large discrepancies between the 4D calculated and measured dose 
distributions, particularly in the off-target structure, were observed when systematic change of 
motion pattern occurred during beam delivery. These results suggest that the accuracy of 4D 
dose calculation, particularly in off-target stationary structure, is strongly tied to the regular-
ity of target motion, and that the solutions of 4D planning do not reflect the clinical nature of 
nonreproducible target motion generally.   
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